MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

MDSpire News

  • August 14, 2026
FDA approves tau PET imaging agent
  • Kathryn Wighton
  • August 14, 2026
  • 2 min

Objective: To report the FDA approval of florquinitau F18 injection (TAUKLARIFY) for tau PET imaging in adults with cognitive impairment undergoing evaluation f

...more
2 min

MDSpire News

  • August 14, 2026
FDA approves iberdomide for multiple myeloma
  • Kathryn Wighton
  • August 14, 2026
  • 3 min
  1. The FDA granted accelerated approval to iberdomide for adults with multiple myeloma who had prior therapy including a proteasome inhibitor and an immunomodulatory agent.
  2. Iberdomide is the first cereblon E3 ligase modulator approved by the FDA and is part of the cereblon-modulating protein degrader class.
  3. The approval was based on the phase 3 EXCALIBER-RRMM trial, which compared iberdomide with daratumumab and dexamethasone to a standard regimen.
  4. At 16 months, 41% of patients receiving the iberdomide regimen achieved MRD-negative complete response compared to 21% in the control group.
  5. Iberdomide has serious adverse reactions, including pneumonia and infections, and carries boxed warnings for embryo-fetal toxicity and thromboembolism.
...more

The Medicine Maker

  • August 14, 2026
Musings from The Power List: John Maher
  • John Maher
  • August 14, 2026
  • 5 min
  1. John Maher's highlight was opening the AERIAL phase 1/2 trial for LEU011, an autologous CAR T-cell therapy for solid tumors.
  2. The main bottleneck in cell and gene therapy is delivery, with issues in manufacturing complexity, cost, and logistics.
  3. Progress in understanding therapy failures includes insights into resistance, antigen escape, and tumor microenvironment suppression.
  4. Regulatory decisions impact the cost and access of therapies, shaping their development and delivery despite not controlling prices.
  5. Successful cell and gene therapy programs must focus on scalable manufacturing, efficient delivery, and early engagement with stakeholders.
...more

The Pathologist

  • August 14, 2026
AI in Pathology Education: Learning as We Go
  • Deeksha Sikri
  • August 14, 2026
  • 6 min
  1. Social media in pathology fostered a community that accelerated collaboration and idea exchange, leading to the development of guidelines.
  2. AI's integration into medical education is driven by individual curiosity rather than a coordinated rollout, creating a unique learning environment.
  3. Educators must define objectives and gather context before utilizing AI tools to enhance learning, similar to the approach in pathology.
  4. AI can assist in educational tasks, but the responsibility for clinical reasoning and judgment remains with the educators.
  5. The current AI moment in education presents an opportunity for educators to engage thoughtfully and shape its impact on learning.
...more

The Pathologist

  • August 14, 2026
UK Report Signals Forensic Staffing Crisis
  • August 14, 2026
  • 3 min
  1. The Royal College of Pathologists report highlights workforce shortages and an aging consultant workforce in UK forensic pathology services.
  2. Consultant numbers in forensic pathology have remained largely unchanged over the past decade despite increasing workloads and case complexity.
  3. The report indicates that 30 percent of the consultant workforce is expected to retire within the next decade, with only 10 residents currently training.
  4. Respondents reported an average workweek of 42 hours, with significant time spent on administration and postmortem examinations.
  5. The report recommends coordinated workforce planning and expanding training capacity to address the challenges faced by forensic pathology services.
...more

The Ophthalmologist

  • August 14, 2026
Combination Therapy in Myopia Control
  • Jan Roelof Polling
  • Trine Møldrup Jakobsen
  • Leila Sara Eppenberger
  • Andrzej Grzybowski
  • August 14, 2026
  • 9 min
  1. Combination therapy is increasingly considered for myopia control, particularly when a child shows ongoing progression despite monotherapy.
  2. Not all children with progressing myopia require combination therapy; many can be effectively managed with monotherapy.
  3. Children at higher risk for myopia progression include those who are younger, have rapid axial elongation, or a strong family history.
  4. Before initiating combination therapy, clinicians should audit treatment adherence and effectiveness to confirm true progression.
  5. Evidence suggests combination therapy may be beneficial, but it should not be viewed as a universal next step for all patients.
...more

The Ophthalmologist

  • August 14, 2026
Santen Joins Global Eye Health Summit
  • August 14, 2026
  • 2 min
  1. Santen Pharmaceutical has joined the inaugural Global Summit for Eye Health as a High Impact Partner.
  2. The summit, organized by IAPB and WHO, will take place in Antigua and Barbuda on November 2, 2026.
  3. Participants will launch the Global Eye Health Compact to accelerate progress through measurable commitments.
  4. Santen plans to unveil its global eye health commitment at the summit to support improvements in eye health.
  5. Over one billion people live with avoidable vision impairment, necessitating coordinated action across various sectors.
...more

Frontiers In Neurology

  • August 14, 2026
Influence of Environmental Factors on Neurotoxicity: The Impact of Heavy Metals in Neurological Conditions
  • Snehashis Mandal
  • Priti Dipa
  • Neha
  • Dhrita Chatterjee
  • Kousik Maparu
  • August 14, 2026

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Frontiers In Psychiatry

  • August 14, 2026
The Frustration Tolerance Breakdown Theory in Substance Use Disorders
  • Yorkiris Mármol Contreras
  • Rocio Sanchez Rivas
  • Shaina Banh
  • Iona C. Duncan
  • Sindhuja Earagolla
  • Thomas A. Green
  • August 14, 2026
  1. Individuals with substance use disorders (SUDs) often continue drug-seeking despite significant frustrations that typically deter others.
  2. The frustration brake failure hypothesis posits that frustration fails to moderate motivation in certain individuals with SUDs.
  3. Frustration serves a biphasic role in drug-seeking behavior, enhancing motivation at low levels and diminishing it at high levels for those without SUDs.
  4. The proposed therapeutic approach aims to target neurobiological mechanisms to restore frustration's role in reducing drug-seeking motivation.
  5. Existing hypotheses on SUDs, like the CNDS and incentive sensitization hypotheses, do not adequately address the role of frustration in motivation.
...more

Frontiers In Digital Health

  • August 14, 2026
Evaluation of Technology-Enhanced Community Lifestyle Interventions for Seniors: Insights from Case Studies Across Six European Regions
  • Irati Erreguerena
  • Nerea González
  • Igor Larrañaga
  • Franco Mercalli
  • Eva Karaglani
  • Yannis Manios
  • Odysseas Androutsos
  • Julia Schellong
  • Kai Gand
  • Rosana Angles Barbastro
  • Maria Teresa Hurtado
  • Gloria Cea
  • Alba Gallego
  • Guiseppe Fico
  • Leandro Pecchia
  • Jordi de Batlle
  • Davide Piaggio
  • Ane Fullaondo
  • August 14, 2026
  1. The GATEKEEPER project evaluated eHealth applications across six European regions to enhance health for older adults.
  2. Community-based interventions were assessed for their implementation processes, focusing on facilitators, barriers, and contextual factors.
  3. Successful interventions relied on user-friendly applications, incentives for engagement, and support from health professionals.
  4. Understanding dropout rates and user adherence is essential for improving the effectiveness of digital health interventions.
  5. Co-designing interventions with user involvement enhances technology alignment with needs, improving engagement and outcomes.
...more

Frontiers In Oncology

  • August 14, 2026
Hidradenocarcinoma of the heel misdiagnosed as a corn for 25 years leading to multiorgan metastasis: a case study and review of existing literature
  • Lianbo Yang
  • Ziang Zheng
  • Haoran Chen
  • Xinyao Cui
  • Jiabin Lin
  • Yifan Wang
  • Haidong Liang
  • Jing Yi
  • August 14, 2026
  1. Hidradenocarcinoma is a rare malignant tumor often misdiagnosed due to nonspecific clinical features, particularly in heel lesions.
  2. A 44-year-old woman had a heel lesion misidentified as a corn for 25 years, leading to delayed diagnosis and treatment.
  3. Histopathological analysis confirmed hidradenocarcinoma after an excisional biopsy, with all surgical margins showing negativity.
  4. The patient developed inguinal and later skeletal and intracranial metastases, highlighting the aggressive nature of the disease.
  5. Timely pathological assessment is crucial for persistent acral lesions to avoid misdiagnosis and ensure appropriate treatment.
...more

Frontiers In Medicine

  • August 14, 2026
Correction: Exudative Retinal Detachment Associated with Acute Retinal Necrosis - A Case Study
  • Han Wang
  • Ying Zhu
  • Ai Xuan Cheng
  • Chao Zhang
  • August 14, 2026

Objective: To correct the authorship of the original case report on acute retinal necrosis presenting exudative retinal detachment. Approach: Authorship Correct

...more
1 min

Frontiers In Medicine

  • August 14, 2026
Utilizing the Behavior Change Wheel for Self-Management in Ulcerative Colitis: A Conceptual Framework for Behavioral Support
  • Zheng-ri Zhu
  • Xue Zhao
  • Chen-chen Wang
  • Jia-yuan Ding
  • Ying He
  • August 14, 2026
  1. Ulcerative colitis (UC) is a chronic inflammatory bowel disease requiring effective self-management due to its unpredictable relapse and remission cycles.
  2. The proposed self-management framework for UC is based on the Behavior Change Wheel (BCW) and the Capability, Opportunity, Motivation-Behavior (COM-B) model.
  3. Five critical self-management behaviors identified include regular follow-up, stress management, symptom monitoring, dietary management, and medication adherence.
  4. The BCW-guided framework aims to create personalized self-management support but requires empirical validation for practical application.
  5. A closed-loop feedback mechanism is proposed to facilitate ongoing behavioral reassessment and support adaptive self-management in UC.
...more

Frontiers In Surgery

  • August 14, 2026
Adult Liver Transplantation Utilizing a Long-Term Mesocaval Shunt for Portal Blood Flow in Congenital Absence of the Portal Vein with Unusual Variceal Hemorrhage and Persistent Shunt Encephalopathy
  • A. V. Shabunin
  • M. G. Minina
  • P. A. Drozdov
  • O. N. Levina
  • S. A. Astapovich
  • D. A. Makeev
  • D. A. Solomatin
  • I. I. Kurbanov
  • A. I. Yurik
  • August 14, 2026

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Frontiers In Oncology

  • August 14, 2026
Longitudinal Imaging Findings in a Patient with SMART Syndrome Following Cranial Radiotherapy: A Case Study
  • Da Bin Kim
  • Haroun Bel Hadj Jrad
  • Lena Bender
  • Jürgen Beck
  • Marcia Machein
  • August 14, 2026
  1. SMART syndrome is a delayed effect of cranial irradiation characterized by migraine-like headaches, seizures, and focal neurological deficits.
  2. A 48-year-old female patient experienced recurrent episodes of focal seizures and unilateral headaches 24 years post-radiotherapy for an anaplastic astrocytoma.
  3. MRI findings showed extensive unilateral gyriform cortical enhancement in the previously irradiated hemisphere, indicating possible SMART syndrome.
  4. Retrospective analysis revealed a milder cortical enhancement episode nine years prior, suggesting earlier manifestations of SMART syndrome.
  5. The presence of cavernous malformations in the patient aligns with chronic radiation-induced microvascular damage and supports a continuum of cortical vulnerability.
...more

Frontiers In Neurology

  • August 14, 2026
Exploring the Role of Photobiomodulation in Addressing Post-Stroke Impairments: A Review of Recent Clinical Research
  • Chao Ren
  • Xiaohong Chi
  • Yuan Jiang
  • August 14, 2026
  1. Photobiomodulation (PBM) is a non-invasive therapy that utilizes red or near-infrared light to manage various neurological disorders.
  2. Recent clinical studies indicate that PBM may improve motor, cognitive, and speech impairments in post-stroke patients.
  3. Transcranial PBM (tPBM) targets cognitive deficits and aphasia, while peripheral PBM addresses limb spasticity and pain.
  4. PBM promotes neurogenesis and triggers anti-apoptotic, anti-inflammatory, and antioxidative responses in the brain.
  5. Despite promising results, strong clinical evidence for PBM's effectiveness in stroke rehabilitation remains limited.
...more

Frontiers In Medicine

  • August 14, 2026
Acute Myeloid Leukemia Induced by Therapy with a 24-Month Latency Following CD19 CAR-T Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Study
  • Manqi Su
  • Chentong Huang
  • Zhanna Zhang
  • Xiaoxia Wang
  • Panruo Jiang
  • Yiran Chen
  • Gongqiang Wu
  • August 14, 2026
  1. Therapy-related acute myeloid leukemia (t-AML) can develop as a late complication of CD19 CAR-T cell therapy, with a notable latency period.
  2. A case study reported t-AML occurring 24 months after CD19 CAR-T therapy in a patient with relapsed/refractory diffuse large B-cell lymphoma.
  3. Genomic monitoring revealed a transition from wild-type TP53 to biallelic loss of TP53 in the patient diagnosed with t-AML.
  4. The patient achieved partial remission of t-AML after treatment with azacitidine and venetoclax, followed by allogeneic stem cell transplantation.
  5. This case highlights the need for ongoing hematologic monitoring and genomic profiling beyond 12 months post-CAR-T therapy.
...more

Frontiers In Oncology

  • August 14, 2026
Correction: Reevaluation of Clinical Trials Involving Selective RET Inhibitors for Thyroid Cancer Treatment
  • Yulu Zhou
  • Junjie Cao
  • Siqi Zhang
  • Mingjun Sun
  • Yaqi Zhang
  • Songzhe Li
  • Zining Luo
  • Pengyu Wang
  • Jiebin Xie
  • August 14, 2026

Objective: To correct the affiliations of author Pengyu Wang in the review and analysis of clinical trials of selective RET inhibitors for thyroid cancer treatm

...more
1 min